Explore by Category

FDA Asked to Approve Use of Multiple Myeloma BMS/bluebird bio CAR T-cell Therapy

MYELOMA NEWS - April 02, 2020

More myeloma patients may soon have access to CAR T-cell therapy because Bristol-Myers Squibb (BMS) and bluebird bio applied to the U.S. Food & Drug Adminis... Read More

A New and Different Approach to Treat Triple Refractory Multiple Myeloma

MYELOMA NEWS - April 02, 2020

The Swedish company Oncopeptides announced interesting news, a few days ago, for those of us who have failed prior treatment with immunomodulators and proteasom... Read More

Genentech Tests Tocilizumab (Used for Cytokine Release Syndrome in Myeloma CAR T Therapy) in Phase III Trial for Severe COVID-19

MYELOMA NEWS - March 23, 2020

Genentech is working with the FDA to launch a Phase III study comparing tocilizumab (Actemra) vs. standard of care in hospitalized adult patients with severe CO... Read More

Cell Therapies for Multiple Myeloma

MYELOMA NEWS - March 12, 2020

There are literally hundreds of clinical trials underway using different cell therapies for the treatment of a variety of cancers. Most of us are aware of some ... Read More

XPOVIO (selinexor) Study Shows Impact When Used in Earlier Lines of Multiple Myeloma Therapy with Velcade and Dex

MYELOMA NEWS - March 11, 2020

Using XPOVIO (selinexor) and Velcade weekly with low-dose dexamethasone showed a 47% increase in progression free survival compared to Velcade (twice weekly) an... Read More

Myeloma Crowd Pledges Support for the Interoperability Rules Finalized Today by the US Department of Health and Human Services

MYELOMA NEWS - March 09, 2020

CrowdCare Founder and Patient Advocate Jenny Ahlstrom Says Patient Access to Data is the Key to Curing Disease SALT LAKE CITY, UT – March 9, 2020 &ndas... Read More

New CD38 Monoclonal Antibody Sarclisa® (isatuximab) Receives FDA Approval for Relapsed Multiple Myeloma

MYELOMA NEWS - March 02, 2020

The FDA today approved a new monoclonal antibody targeting CD38 for the treatment of relapsed and refractory multiple myeloma patients. Sarclisa® (isatuximab) ... Read More

Better Gut Diversity Before Allo Transplant Lowers Death Rate for Blood Cancer Patients

MYELOMA NEWS - February 28, 2020

A recent study of over 1,300 Allogeneic (donor) transplant patients with blood cancers (including multiple myeloma - 8% of the patients) showed that patients w... Read More

Myeloma Community Loses Myeloma Great, Dr. Phillip Greipp of the Mayo Clinic Rochester

MYELOMA NEWS - February 27, 2020

Philip Robert Greipp, M.D., 77, passed away Tuesday evening, Feb. 11 at Fairview Southdale Hospital in Edina, from complications of an acute illness and a previ... Read More

Making a safer CAR-T

MYELOMA NEWS - February 26, 2020

Prior posts on Myeloma Crowd have already mentioned that patients undergoing therapy with current CAR-T constructs have a good chance to experience a side effec... Read More

Natural Killer Cells to Fight Multiple Myeloma

MYELOMA NEWS - February 19, 2020

Scientific progress in treating multiple myeloma has been moving forward over the past few years at a speed not seen in the more distant past. We have become fa... Read More

New Vaccine Reduces Complications of Chicken Pox and Mono-Related Virus in Transplant Multiple Myeloma Patients

MYELOMA NEWS - February 18, 2020

Most folks over 40 walk around with Cytomegalovirus (CMV) and don't even know about it because it rarely causes problems in healthy people. CMV is related to th... Read More

New Myeloma Combo (carfilzomib/dara/dex) Submitted for FDA Approval

MYELOMA NEWS - February 12, 2020

A new combination of multiple myeloma therapies has been submitted for FDA approval this week. Janssen submitted the request to the FDA for the use of daratumum... Read More

Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies